These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39141986)

  • 1. Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases.
    N MS; Álvarez-Troncoso J; Robles-Marhuenda Á; De la Calle Fernández-Miranda M; Muner Hernando ML; Bartha JL
    J Autoimmun; 2024 Sep; 148():103301. PubMed ID: 39141986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases.
    Brites L; Madeira N; Rodrigues J; Marona J; Martins N; Águeda A; Freitas R; Neto A; Capela S; Sequeira G; Ganhão S; Duarte C; Santiago M; Santos MJ
    Acta Reumatol Port; 2019; 44(4):266-272. PubMed ID: 32008032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare.
    Allen KD; Kiefer MK; Butnariu M; Afzali A
    Arch Gynecol Obstet; 2022 Dec; 306(6):1929-1937. PubMed ID: 35249153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perinatal Use and Discontinuation of Disease-Modifying Antirheumatic Drugs: Outcomes of Patients Seen at a Pregnancy and Rheumatic Diseases Clinic.
    Rebić N; De Vera MA; Gupta A; Amiri N
    J Clin Rheumatol; 2024 Aug; 30(5):188-192. PubMed ID: 38753224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
    Simon D; Tascilar K; Kleyer A; Fagni F; Krönke G; Meder C; Dietrich P; Orlemann T; Kliem T; Mößner J; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
    Arthritis Rheumatol; 2022 May; 74(5):783-790. PubMed ID: 34951137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation.
    Levy RA; de Jesús GR; de Jesús NR; Klumb EM
    Autoimmun Rev; 2016 Oct; 15(10):955-63. PubMed ID: 27490204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
    Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
    Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
    Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
    Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.
    Andreoli L; Gerardi MC; Gerosa M; Rozza D; Crisafulli F; Erra R; Lini D; Trespidi L; Padovan M; Ruffilli F; Serale F; Cuomo G; Raffeiner B; Semeraro P; Tani C; Chimenti MS; Conigliaro P; Hoxha A; Nalli C; Fredi M; Lazzaroni MG; Filippini M; Taglietti M; Franceschini F; Zatti S; Loardi C; Orabona R; Ramazzotto F; Zanardini C; Fontana G; Gozzoli G; Barison C; Bizioli P; Caporali RF; Carrea G; Ossola MW; Maranini B; Silvagni E; Govoni M; Morano D; Verteramo R; Doria A; Del Ross T; Favaro M; Calligaro A; Tonello M; Larosa M; Zen M; Zambon A; Mosca M; Zucchi D; Elefante E; Gori S; Iannone F; Anelli MG; Lavista M; Abbruzzese A; Fasano CG; D'Angelo S; Cutro MS; Picerno V; Carbone T; Padula AA; Rovere-Querini P; Canti V; De Lorenzo R; Cavallo L; Ramoni V; Montecucco C; Codullo V; Milanesi A; Pazzola G; Comitini G; Marvisi C; Salvarani C; Epis OM; Benedetti S; Di Raimondo G; Gagliardi C; Lomater C; Crepaldi G; Bellis E; Bellisai F; Garcia Gonzalez E; Pata AP; Zerbinati M; Urban ML; Mattioli I; Iuliano A; Sebastiani G; Brucato AL; Bizzi E; Cutolo M; Santo L; Tonetta S; Landolfi G; Carrara G; Bortoluzzi A; Scirè CA; Tincani A;
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy.
    Cooper WO; Cheetham TC; Li DK; Stein CM; Callahan ST; Morgan TM; Shintani AK; Chen N; Griffin MR; Ray WA
    Arthritis Rheumatol; 2014 Feb; 66(2):444-50. PubMed ID: 24504818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal-fetal outcomes in patients with immune-mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system.
    Hwang YM; Wei Q; Piekos SN; Vemuri B; Molani S; Mease P; Hood L; Hadlock J
    EClinicalMedicine; 2024 Feb; 68():102435. PubMed ID: 38586478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
    Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
    Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
    Götestam Skorpen C; Hoeltzenbein M; Tincani A; Fischer-Betz R; Elefant E; Chambers C; da Silva J; Nelson-Piercy C; Cetin I; Costedoat-Chalumeau N; Dolhain R; Förger F; Khamashta M; Ruiz-Irastorza G; Zink A; Vencovsky J; Cutolo M; Caeyers N; Zumbühl C; Østensen M
    Ann Rheum Dis; 2016 May; 75(5):795-810. PubMed ID: 26888948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying anti-rheumatic drug use in pregnant women with rheumatic diseases: a systematic review of the risk of congenital malformations.
    Baldwin C; Avina-Zubieta A; Rai SK; Carruthers E; De Vera MA
    Clin Exp Rheumatol; 2016; 34(2):172-83. PubMed ID: 26940667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
    Tageldin M; Wilson N; Yin Y; Sharma TS
    Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis.
    Barenbrug L; Groen MT; Hoentjen F; van Drongelen J; Reek JMPAVD; Joosten I; de Jong EMGJ; van der Molen RG
    J Autoimmun; 2021 Aug; 122():102676. PubMed ID: 34126302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
    Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
    Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
    Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
    Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.